A candidate Covid-19 vaccine referred to as EpiVacCorona, Russia’s second to be registered, proved “100% effective” in early-stage trials, Russian consumer health watchdog Rospotrebnadzor has told local media.

The data, supported phase I clinical trial and II trials, were released before the beginning of a bigger phase III clinical trial trial which might normally involve thousands of participants and a placebo group as a comparison.

“The effectiveness of the vaccine is formed from its immunological effectiveness and preventative effectiveness,” the TASS press agency reported, citing Rospotrebnadzor.

“According to results of the primary and second phases of clinical trials, the immunological effectiveness of the EpiVacCorona vaccine is 100%.”

The phase I clinical trial and II studies tested the security , side-effects and immunogenicity of the potential vaccine in 100 people aged 18-60, consistent with the state trials register.

Typically early-stage vaccine tests on humans are supported blood readings showing an immune reaction in participants who haven’t been exposed to the virus, while the results of larger late-stage trials are supported actual infections suffered by participants in their normal lives.

Russia began testing EpiVacCorona, which is being developed by Siberia’s Vector Institute, in November.

Earlier that month, Moscow said its other approved vaccine, Sputnik V, was 92% effective at protecting people from Covid-19 supported interim results.

Russia has said it can inoculate 60% of its population against Covid-19 this year, and although the Sputnik V vaccine has been readily available in Moscow, the rollout across the country has been slow.

Russian President Putin has ordered mass vaccinations to start out in the week .

EpiVacCorona are going to be utilized in mass vaccinations from March, Deputy Prime Minister Tatiana Golikova told the Interfax press agency .

Russia has reported 3,612,800 coronavirus cases, the world’s fourth-highest total. Its price from the virus stands at 66,623.

LEAVE A REPLY

Please enter your comment!
Please enter your name here